Publication

Video

Supplements and Featured Publications
Targeted Advances in ALK+ NSCLC
Volume 1
Issue 1

Dr. Stinchcombe on Remaining Challenges in ALK+ NSCLC

Thomas E. Stinchcombe, MD, discusses remaining challenges in ALK-positive non­–small cell lung cancer.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses remaining challenges in ALK-positive non­—small cell lung cancer (NSCLC).

Though patients are responding well to upfront next-generation TKIs, the optimal treatment strategy for patients who experience disease progression is unclear, says Stinchcombe.

Chemotherapy or single-agent lorlatinib (Lorbrena) are potential regimens with response rates around 40% to 45% and a progression-free survival benefit of 6 to 8 months, explains Stinchcombe. Importantly, lorlatinib has a high rate of central nervous system activity that may benefit patients with brain metastases.

Remaining questions regarding repeat tumor biopsy, the utility of circulating tumor DNA, and how to further personalize treatment for patients need to be explored further, highlights Stinchcombe.

Additionally, up to 50% of patients will not have an ALK mutation either because insensitive testing did not catch a mutation, or because the patient has ALK-independent mechanisms of resistance. Understanding the optimal treatment for these patients is critical going forward, Stinchcombe concludes.

Related Videos
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Noman Ashraf, MD
Ivy Riano, MD, of Dartmouth Geisel School of Medicine
Daniel E. Haggstrom, MD
Daniel E. Haggstrom, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.